Injection Pen Market by Type (Disposable and Reusable Pens), Therapy (Diabetes Therapy (Insulin, GLP-1), Growth Hormone Therapy, Osteoporosis, obesity, fertility), End User (Homecare and Hospitals & Clinics), and Region - Global Forecast to 2030
세계 인젝션 펜 시장 규모는 2024년 470억 달러에서 2030년 741억 달러에 달할 것으로 예상되며, 예측 기간 동안 7.9%의 CAGR을 기록할 것으로 예상됩니다.
전 세계 노인 인구의 급증과 당뇨병, 성장호르몬 장애와 같은 만성 질환 환자의 급격한 증가는 인젝션 펜 시장의 수요를 증가시킬 것으로 예상됩니다. 또한, 자가 투약의 점진적인 증가와 환자 중심적 징후와 환자 순응도에 초점을 맞춘 자가 투약의 사용이 점차 증가하면서 시장 성장을 뒷받침할 것으로 보입니다. 인젝션 펜 기술 발전, 신제품 출시, 유리한 상환 및 정부 정책, 의료 인프라에 대한 투자, 인젝션 펜의 접근성과 경제성을 강화하기 위한 이니셔티브는 시장 성장을 촉진할 것으로 예상됩니다.
| 조사 범위 |
| 조사 대상 연도 |
2024-2030년 |
| 기준 연도 |
2023년 |
| 예측 기간 |
2024-2030년 |
| 검토 단위 |
금액(10억 달러) |
| 부문 |
유형별, 치료법별, 최종사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
인젝션 펜 시장에서 재사용 가능한 인젝션 펜 부문은 예측 기간 동안 상당한 속도로 성장할 것으로 예상됩니다. 만성 질환의 유병률 증가, 재사용 가능한 인젝션 펜의 사용 편의성 및 내구성으로 인해 재사용 가능한 인젝션 펜 부문은 예측 기간 동안 상당한 속도로 성장할 것으로 예상됩니다. 이 펜은 약물 카트리지를 교체하여 여러 번 사용할 수 있기 때문에 일회용 펜보다 경제적입니다. 또한, 자가 투약 및 재택 치료에 대한 선호도가 높아지면서 재사용 가능한 인젝션 펜의 개발과 발전이 두드러지게 나타나고 있습니다. 이러한 요인들은 약물전달의 성장을 가속화하고 있습니다.
치료법별로 주사제 시장은 당뇨병, 성장호르몬 치료, 불임 치료, 골다공증, 비만 및 기타 치료로 분류됩니다. 당뇨병 분야는 인슐린 치료와 GLP-1 치료로 세분화되며, GLP-1 부문은 예측 기간 동안 높은 CAGR을 기록할 것으로 예상됩니다. GLP-1 기반 치료제는 생리학적 특성으로 인해 당뇨병 치료에 사용되며, 가늘고 짧은 바늘을 사용하는 펜형 장치를 통해 투여됩니다. GLP-1 치료제를 개발하기 위한 저명한 시장 진입 기업들의 높은 R&D 투자와 GLP-1 인젝션 펜에 대한 최근 동향은 이 부문의 성장을 촉진할 것으로 예상됩니다.
세계 인젝션 펜 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카의 5개 주요 지역으로 분류됩니다. 북미는 인젝션 펜의 가장 큰 지역 시장이며, 아시아태평양 시장은 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다.
이 보고서는 세계 인젝션 펜 시장을 조사하여 유형별, 치료법별, 최종사용자별, 지역별 동향, 시장 진입 기업 개요 등을 정리한 보고서입니다.
목차
제1장 소개
제2장 조사 방법
제3장 주요 요약
제4장 주요 인사이트
제5장 시장 개요
- 시장 역학
- 고객의 비즈니스에 영향을 미치는 동향/혼란
- 기술 분석
- 공급망 분석
- 무역 분석
- Porter's Five Forces 분석
- 밸류체인 분석
- 규제 상황
- 특허 분석
- 가격 분석
- 2024-2025년의 주요 회의와 이벤트
- 주요 이해관계자와 구입 기준
- 생태계 분석
- 사례 연구 분석
- 상환 분석
- 인젝션 펜 시장의 미충족 수요
- 인젝션 펜 시장의 최종사용자 기대
- 인젝션 펜 시장의 AI의 영향
- 투자와 자금 조달 시나리오
제6장 인젝션 펜 시장(유형별)
제7장 인젝션 펜 시장(치료법별)
- 소개
- 당뇨병
- 성장호르몬 요법
- 골다공증
- 불임
- 비만
- 기타
제8장 인젝션 펜 시장(최종사용자별)
제9장 인젝션 펜 시장(지역별)
- 소개
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
제10장 경쟁 상황
- 개요
- 주요 진출 기업 전략/비책
- 매출 분석
- 시장 점유율 분석
- 기업 평가 매트릭스 : 주요 진출 기업, 2023년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
- 기업 가치 평가와 재무 지표
- 브랜드/제품 비교
- 경쟁 시나리오
제11장 기업 개요
- 주요 진출 기업
- NOVO NORDISK A/S
- ELI LILLY AND COMPANY
- SANOFI
- YPSOMED HOLDING AG
- BECTON, DICKINSON AND COMPANY
- MERCK KGAA
- ASTRAZENECA
- OWEN MUMFORD
- HASELMEIER
- SUN PHARMACEUTICAL INDUSTRIES LTD.
- PFIZER INC.
- BIOCON
- LUPIN
- WOCKHARDT LTD.
- MEDTRONIC
- 기타 기업
- GERRESHEIMER AG
- SHAILY ENGINEERING PLASTICS LTD.
- SHL MEDICAL AG
- EMPERRA GMBH E-HEALTH TECHNOLOGIES
- NEMERA FRANCE SAS
- JIANGSU DELFU MEDICAL DEVICE CO., LTD.
- SOLTEAM MEDICAL
- PHILLIPS-MEDISIZE-A MOLEX COMPANY
- STEVANATO GROUP
- WANHAI MEDICAL INSTRUMENTS CO., LTD.
제12장 부록
ksm
The global injection pen market is projected to reach USD 74.1 billion by 2030 from USD 47.0 billion in 2024, at a CAGR of 7.9% during the forecast period. The rapid growth in the geriatric population globally and the significant rise in the patients with chronic diseases such as diabetes and growth hormone disorders are expected to boost the demand for injection pen market. Moreover, gradual rise in utilization of self administration and increased focus on patient centric dsign and patient compliance are likely to support the market growth. Advancements in injection pen technology, new product launches, favourable reimbursement and government policies, investments in healthcare infrastructure, and initiatives to enhance the accessibility and affordability of injection pen is anticipated to fuel the market growth.
| Scope of the Report |
|---|
| Years Considered for the Study | 2024-2030 |
| Base Year | 2023 |
| Forecast Period | 2024-2030 |
| Units Considered | Value (USD Billion) |
| Segments | Type, Therapy, End User, and Region |
| Regions covered | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
"The reusable injection pen segment of injection pen market to grow with the highest CAGR during the forecast period."
Based on the injection pen market, the reusable injection pen segment is anticipated to grow at significant rate during forecast period. Due to increasing prevalence of chronic disease, ease of use and durability of reusable injection pen. These pens are more economical than disposable pens as they can be used multiple times by replacing the drug cartridge.Also, due to increased preference in self-administration and home care, there has been significant development and advancement in reusable injection pens. These factors are fostering the growth of injectable drug delivery at higher pace.
"The GLP-1 segment of diabetes therapy type segment to capture the largest market share of injection pen market."
Based on therapy the injection pen market is segmented into into diabetes, growth hormone therapy, fertility, osteoporosis, obesity, and other therapies. The diabetes segment is further segmented into insulin and GLP-1 therapy types. GLP-1 segment register the higher CAGR during the forecast period. GLP-1-based therapies are used in treating diabetes mellitus due to their physiological properties and delivered through pen devices using thin and short needles. Owing to high R&D investments for developing GLP-1 therapies by prominent market players and recent advancements in GLP-1 injection pens are likely to propel the growth of this segment.
"North America accounted for the largest share of the injection pen market by region."
The global injection penmarket is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest regional market for injection pen, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.
The largest share of North America is attributed to the high disease burden of chronic disease such as diabetes contributing to a larger pool of patients requiring injection pen products. The presence of numerous potential market giants and favorable reimbursement policy in the region is likely to promote the growth of injection pen market in North America.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1-25%, Tier 2-30%, and Tier 3- 45%
- By Designation: C-level-26%, Director-level-30%, and Others-44%
- By Region: North America-40%, Europe-31%, Asia Pacific-20%, Latin America-6%, and the Middle East & Africa-3%
The major players operating in the injection pen market market are Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), Ypsomed Holding AG (Switzerland), Becton, Dickinson and Company (US), Merck KGaA (Germany), AstraZeneca (UK), Owen Mumford (UK), Heselmeier (Germany), Sun Pharmaceutical Industries Ltd. (India), Pfizer Inc. (US), Biocon (India), Lupin (India), Wockhardt Ltd. (India) and Medtronic (Ireland).
Research Coverage
This report studies the injection pen market based on type, therapy, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
- Analysis of Key divers (increasing prevalence of chronic disease, technological advancement in injection pens, new product launches, favourable reimbursement scenario and government initiatives), restraints (stringent regulatory requirement , Opportunities (emerging markets, increasing focus on patient centric design and connected device ) , Challenge (lack of training and awareness, risk of injection site reactions)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the injection pen market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the injection pen market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the injection pen market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.2.1 INCLUSIONS AND EXCLUSIONS
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 YEARS CONSIDERED
- 1.3.3 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Key industry insights
- 2.1.2.2 Breakdown of primary interviews
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 FINISHED FORMULATIONS
- 2.2.2 INJECTION PEN DEVICES
- 2.2.2.1 Top-down approach
- 2.3 GROWTH RATE PROJECTIONS
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.6.1 PARAMETRIC LIMITATIONS
- 2.6.2 SCOPE-RELATED LIMITATIONS
- 2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 INJECTION PEN MARKET OVERVIEW
- 4.2 ASIA PACIFIC: INJECTION PEN MARKET, BY THERAPY AND COUNTRY, 2023
- 4.3 INJECTION PEN MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 4.4 INJECTION PEN MARKET: DEVELOPED VS. DEVELOPING MARKETS
5 MARKET OVERVIEW
- 5.1 MARKET DYNAMICS
- 5.1.1 DRIVERS
- 5.1.1.1 Surge in chronic diseases
- 5.1.1.2 Favorable reimbursement and government support
- 5.1.1.3 Emergence of new technologies
- 5.1.2 RESTRAINTS
- 5.1.2.1 Stringent regulatory requirements
- 5.1.3 OPPORTUNITIES
- 5.1.3.1 Rising focus on patient-centric design and connected devices
- 5.1.3.2 Growth opportunities in emerging economies
- 5.1.4 CHALLENGES
- 5.1.4.1 Lack of training and education
- 5.1.4.2 Need to minimize side effects and injection-site reactions
- 5.2 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.3 TECHNOLOGY ANALYSIS
- 5.3.1 KEY TECHNOLOGIES
- 5.3.1.1 Connectivity and smart features
- 5.3.1.2 Pen injector materials
- 5.3.2 COMPLEMENTARY TECHNOLOGIES
- 5.3.2.1 In-built functions
- 5.3.2.2 Wireless connectivity
- 5.3.2.3 Smart caps and attachments
- 5.3.3 ADJACENT TECHNOLOGIES
- 5.3.3.1 Autoinjectors
- 5.3.3.2 Insulin pumps
- 5.3.3.3 Wearable insulin injectors
- 5.4 SUPPLY CHAIN ANALYSIS
- 5.5 TRADE ANALYSIS
- 5.5.1 IMPORT DATA
- 5.5.2 EXPORT DATA
- 5.6 PORTER'S FIVE FORCES ANALYSIS
- 5.6.1 INTENSITY OF COMPETITIVE RIVALRY
- 5.6.2 BARGAINING POWER OF SUPPLIERS
- 5.6.3 BARGAINING POWER OF BUYERS
- 5.6.4 THREAT OF SUBSTITUTES
- 5.6.5 THREAT OF NEW ENTRANTS
- 5.7 VALUE CHAIN ANALYSIS
- 5.8 REGULATORY LANDSCAPE
- 5.8.1 NORTH AMERICA
- 5.8.1.1 US
- 5.8.1.2 Canada
- 5.8.2 EUROPE
- 5.8.3 ASIA PACIFIC
- 5.8.3.1 Japan
- 5.8.3.2 China
- 5.8.3.3 India
- 5.8.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.9 PATENT ANALYSIS
- 5.9.1 PATENT PUBLICATION TRENDS FOR INJECTION PENS
- 5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS
- 5.10 PRICING ANALYSIS
- 5.10.1 AVERAGE SELLING PRICE OF INSULIN PENS, BY KEY PLAYER
- 5.10.2 AVERAGE SELLING PRICE OF GLP-1 PENS, BY KEY PLAYER
- 5.10.3 AVERAGE SELLING PRICE, BY THERAPY
- 5.10.4 AVERAGE SELLING PRICE, BY REGION
- 5.11 KEY CONFERENCES AND EVENTS, 2024-2025
- 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.12.2 BUYING CRITERIA
- 5.13 ECOSYSTEM ANALYSIS
- 5.14 CASE STUDY ANALYSIS
- 5.15 REIMBURSEMENT ANALYSIS
- 5.16 UNMET NEEDS IN INJECTION PEN MARKET
- 5.17 END-USER EXPECTATIONS IN INJECTION PEN MARKET
- 5.18 IMPACT OF AI ON INJECTION PEN MARKET
- 5.19 INVESTMENT AND FUNDING SCENARIO
6 INJECTION PEN MARKET, BY TYPE
- 6.1 INTRODUCTION
- 6.2 DISPOSABLE INJECTION PENS
- 6.2.1 GROWING GERIATRIC POPULATION TO DRIVE MARKET
- 6.3 REUSABLE INJECTION PENS
- 6.3.1 ONGOING TECHNOLOGICAL ADVANCEMENTS TO FUEL MARKET
7 INJECTION PEN MARKET, BY THERAPY
- 7.1 INTRODUCTION
- 7.2 DIABETES
- 7.2.1 INSULIN
- 7.2.1.1 Rising prevalence of diabetes to aid market growth
- 7.2.2 GLUCAGON-LIKE PEPTIDE-1
- 7.2.2.1 Rising focus on research & development to propel market
- 7.3 GROWTH HORMONE THERAPY
- 7.3.1 INCREASED SUPPORT FOR CO-PAYMENT OF DRUG DELIVERY SERVICES TO FUEL MARKET
- 7.4 OSTEOPOROSIS
- 7.4.1 GROWING UPTAKE FOR TREATING BONE ISSUES TO SUPPORT MARKET
- 7.5 FERTILITY
- 7.5.1 CHANGING LIFESTYLE AND RISING INCIDENCE OF IMPOTENCE TO BOOST DEMAND
- 7.6 OBESITY
- 7.6.1 RISING PREVALENCE OF OBESITY IN HIGH-INCOME COUNTRIES TO DRIVE MARKET
- 7.7 OTHER THERAPIES
8 INJECTION PEN MARKET, BY END USER
- 8.1 INTRODUCTION
- 8.2 HOME CARE SETTINGS
- 8.2.1 TREND OF SELF-ADMINISTRATION TO STIMULATE GROWTH
- 8.3 HOSPITALS & CLINICS
- 8.3.1 NEEDLESTICK INJURIES AND UNSAFE INJECTION PRACTICES TO PROPEL DEMAND
9 INJECTION PEN MARKET, BY REGION
- 9.1 INTRODUCTION
- 9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.1.1 Increasing prevalence of diabetes and infertility to drive market
- 9.2.2 CANADA
- 9.2.2.1 Booming healthcare expenditure to fuel market
- 9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.1.1 Advanced healthcare system and insurance coverage to boost market
- 9.3.2 FRANCE
- 9.3.2.1 Growing incidence of chronic diseases to foster growth
- 9.3.3 UK
- 9.3.3.1 Rising focus on educating patients and staff about safe use of injection pens to aid growth
- 9.3.4 ITALY
- 9.3.4.1 Heterogenous reimbursement policies to hinder market growth
- 9.3.5 SPAIN
- 9.3.5.1 Favorable healthcare regulations to aid growth
- 9.3.6 REST OF EUROPE
- 9.4 ASIA PACIFIC
- 9.4.1 JAPAN
- 9.4.1.1 Universal healthcare coverage to fuel market
- 9.4.2 CHINA
- 9.4.2.1 Growing focus on public health services to support market growth
- 9.4.3 INDIA
- 9.4.3.1 Rapid population growth to drive market
- 9.4.4 SOUTH KOREA
- 9.4.4.1 Surge in collaborations among companies to increase adoption of injectables
- 9.4.5 AUSTRALIA
- 9.4.5.1 Increasing regulatory approvals to augment growth
- 9.4.6 REST OF ASIA PACIFIC
- 9.5 LATIN AMERICA
- 9.5.1 BRAZIL
- 9.5.1.1 Surge in obesity issues to stimulate market growth
- 9.5.2 MEXICO
- 9.5.2.1 Increasing incidence of chronic diseases to drive growth
- 9.5.3 REST OF LATIN AMERICA
- 9.6 MIDDLE EAST & AFRICA
- 9.6.1 GCC COUNTRIES
- 9.6.1.1 Growing preference among patients for self-administration to drive market
- 9.6.2 REST OF MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
- 10.1 OVERVIEW
- 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INJECTION PEN MARKET
- 10.3 REVENUE ANALYSIS
- 10.4 MARKET SHARE ANALYSIS
- 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 10.5.1 STARS
- 10.5.2 EMERGING LEADERS
- 10.5.3 PERVASIVE PLAYERS
- 10.5.4 PARTICIPANTS
- 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 10.5.5.1 Company footprint
- 10.5.5.2 Type footprint
- 10.5.5.3 Therapy footprint
- 10.5.5.4 Region footprint
- 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 10.6.1 PROGRESSIVE COMPANIES
- 10.6.2 RESPONSIVE COMPANIES
- 10.6.3 DYNAMIC COMPANIES
- 10.6.4 STARTING BLOCKS
- 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 10.7 COMPANY VALUATION AND FINANCIAL METRICS
- 10.7.1 FINANCIAL METRICS
- 10.7.2 COMPANY VALUATION
- 10.8 BRAND/PRODUCT COMPARISON
- 10.9 COMPETITIVE SCENARIO
- 10.9.1 PRODUCT LAUNCHES AND APPROVALS
- 10.9.2 DEALS
- 10.9.3 EXPANSIONS
- 10.9.4 OTHER DEVELOPMENTS
11 COMPANY PROFILES
- 11.1 KEY PLAYERS
- 11.1.1 NOVO NORDISK A/S
- 11.1.1.1 Business overview
- 11.1.1.2 Products offered
- 11.1.1.3 Recent developments
- 11.1.1.3.1 Product launches and approvals
- 11.1.1.3.2 Deals
- 11.1.1.4 MnM view
- 11.1.1.4.1 Key strengths
- 11.1.1.4.2 Strategic choices
- 11.1.1.4.3 Weaknesses and competitive threats
- 11.1.2 ELI LILLY AND COMPANY
- 11.1.2.1 Business overview
- 11.1.2.2 Products offered
- 11.1.2.3 Recent developments
- 11.1.2.3.1 Deals
- 11.1.2.3.2 Expansions
- 11.1.2.4 MnM view
- 11.1.2.4.1 Key strengths
- 11.1.2.4.2 Strategic choices
- 11.1.2.4.3 Weaknesses and competitive threats
- 11.1.3 SANOFI
- 11.1.3.1 Business overview
- 11.1.3.2 Products offered
- 11.1.3.3 Recent developments
- 11.1.3.4 MnM view
- 11.1.3.4.1 Key strengths
- 11.1.3.4.2 Strategic choices
- 11.1.3.4.3 Weaknesses and competitive threats
- 11.1.4 YPSOMED HOLDING AG
- 11.1.4.1 Business overview
- 11.1.4.2 Products offered
- 11.1.4.3 Recent developments
- 11.1.4.3.1 Expansions
- 11.1.4.3.2 Other developments
- 11.1.4.4 MnM view
- 11.1.4.4.1 Key strengths
- 11.1.4.4.2 Strategic choices
- 11.1.4.4.3 Weaknesses and competitive threats
- 11.1.5 BECTON, DICKINSON AND COMPANY
- 11.1.5.1 Business overview
- 11.1.5.2 Products offered
- 11.1.5.3 MnM view
- 11.1.5.3.1 Key strengths
- 11.1.5.3.2 Strategic choices
- 11.1.5.3.3 Weaknesses and competitive threats
- 11.1.6 MERCK KGAA
- 11.1.6.1 Business overview
- 11.1.6.2 Products offered
- 11.1.7 ASTRAZENECA
- 11.1.7.1 Business overview
- 11.1.7.2 Products offered
- 11.1.7.3 Recent developments
- 11.1.7.3.1 Product launches and approvals
- 11.1.8 OWEN MUMFORD
- 11.1.8.1 Business overview
- 11.1.8.2 Products offered
- 11.1.9 HASELMEIER
- 11.1.9.1 Business overview
- 11.1.9.2 Products offered
- 11.1.10 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 11.1.10.1 Business overview
- 11.1.10.2 Products offered
- 11.1.11 PFIZER INC.
- 11.1.11.1 Business overview
- 11.1.11.2 Products offered
- 11.1.12 BIOCON
- 11.1.12.1 Business overview
- 11.1.12.2 Products offered
- 11.1.12.3 Recent developments
- 11.1.12.3.1 Product launches and approvals
- 11.1.12.3.2 Deals
- 11.1.13 LUPIN
- 11.1.13.1 Business overview
- 11.1.13.2 Products offered
- 11.1.14 WOCKHARDT LTD.
- 11.1.14.1 Business overview
- 11.1.14.2 Products offered
- 11.1.15 MEDTRONIC
- 11.1.15.1 Business overview
- 11.1.15.2 Products offered
- 11.1.15.3 Recent developments
- 11.1.15.3.1 Product launches and approvals
- 11.2 OTHER PLAYERS
- 11.2.1 GERRESHEIMER AG
- 11.2.2 SHAILY ENGINEERING PLASTICS LTD.
- 11.2.3 SHL MEDICAL AG
- 11.2.4 EMPERRA GMBH E-HEALTH TECHNOLOGIES
- 11.2.5 NEMERA FRANCE SAS
- 11.2.6 JIANGSU DELFU MEDICAL DEVICE CO., LTD.
- 11.2.7 SOLTEAM MEDICAL
- 11.2.8 PHILLIPS-MEDISIZE - A MOLEX COMPANY
- 11.2.9 STEVANATO GROUP
- 11.2.10 WANHAI MEDICAL INSTRUMENTS CO., LTD.
12 APPENDIX
- 12.1 DISCUSSION GUIDE
- 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 12.3 CUSTOMIZATION OPTIONS
- 12.4 RELATED REPORTS
- 12.5 AUTHOR DETAILS
